← Leaderboards
Patricia J Holman
Texas A&M University System
$222,801
Attributed
$222,801
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $28.3K · FY2005–10$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$222,801 · 7
By mechanism
R03$145,500 · 1
M01$77,301 · 6
Top collaborators
No co-investigators on record.
Most similar at Texas A&M University System
Same institution · by research overlap
- Eric E Simanek$2,570,132
- Guan Zhu$5,664,174
Others in their field
Top investigators on “United States National Institutes Of Health”
- Leonard Freedman · Leidos Biomedical Research, Inc.$816,847,401
- Sonia M Thomas · Research Triangle Institute$701,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$642,073,624
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$513,687,120
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United States National Institutes Of HealthInstitutionFundingGrantResourcesComputer Retrieval Of Information On Scientific Projects DatabaseSourceResearch PersonnelTransplantationPeripheral Blood Stem CellAmd3100Csf3 GeneComputer Assisted Sequence AnalysisAnimal TissueBabesiosisMicroorganism CultureNucleic Acid PurificationNucleic Acid SequenceGeographic SiteBabesiaGenetic StrainClinical ResearchClinical TrialsLife
Grant awards (10)
AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS$1,726
M01 · FY2010 · RR · contact PI
AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS$28,310
M01 · FY2009 · RR · contact PI
AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS$6,869
M01 · FY2008 · RR · contact PI
AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS$2,326
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF TUMOR-SPECIFIC IDIOTYPE AND SOLUBLE GM-CSF VACCINATION$1,163
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF TUMOR-SPECIFIC IDIOTYPE AND SOLUBLE GM-CSF VACCINATION$6,832
M01 · FY2006 · RR · contact PI
PHASE II STUDY OF TUMOR-SPECIFIC IDIOTYPE AND SOLUBLE GM-CSF VACCINATION$17,094
M01 · FY2005 · RR
Comparison of US and European Babesia divergens Isolates$72,750
R03 · FY2004 · AI
Phase II Tumor-Specific Idiotype/Soluble GM-CSF Vaccine$12,981
M01 · FY2004 · RR
Comparison of US and European Babesia divergens Isolates$72,750
R03 · FY2003 · AI